Omeros (OMER) to Release Quarterly Earnings on Monday

Omeros (NASDAQ:OMER) is expected to be announcing its earnings results after the market closes on Monday, March 24th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter.

Omeros Stock Performance

Shares of Omeros stock opened at $9.10 on Friday. The company has a 50 day moving average of $8.70 and a 200-day moving average of $7.32. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60. The company has a market cap of $527.35 million, a PE ratio of -3.94 and a beta of 2.03.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on OMER shares. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Friday. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Friday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.